Below is an excerpt from the article. Full access is provided with an upgrade.
In our survey of law firms last month , respondents claimed new, insurance-backed funding products entering the market are the biggest risk to traditional funders. Such products aim to provide a lower cost of capital to law firms and plaintiffs compared to Burford and funders. Over the last month, we’ve spoken to various brokers, carriers, and lenders to understand how and why insurance-backed financing may be a risk to BUR.
Insurance products have existed for decades in legal finance. Funders and law firms insure all types of risks across pre, post, or adverse judgment assets. There are broadly three types of insurance products in the market:
Funders insuring single cases or portfolios
Judgment Preservation Insurance (JPI)
Pre-judgment insurance of single cases and portfolios for law firms and plaintiffs
Funders insuring certain risks in their portfolio is the largest and most mature market with JPI the second largest. Pre-judgment insurance-backed financing are newer products launched within the last 2 years and seem to be the biggest potential risk to funders. This piece of research shares our learnings on how JPI and pre-judgment insurance works and the potential risk to BUR.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research